Reivindicaciones

1. A composition comprising an iNOS (inducible nitric oxide synthase) inhibitor for use in the prophylactic or therapeutic treatment of a thoracic aortic aneurysm (TAA) in a human patient, wherein the iNOS inhibitor is selected from the group consisting of 1400W (N'-[[3-(aminomethyl)phenyl]methyl]ethanimidamide), GW274150 ((2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid), GW273629 ((2R)-2-amino-3-[2-(1-aminoethylideneamino)ethylsulfonyl]propanoic acid), Aminoguanidine (AG) (2-aminoguanidine), L-NIL ((2S)-2-amino-6-(1-aminoethylideneamino)hexanoic acid), clotrimazole and L-NAME (methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate), or any pharmaceutically acceptable salts thereof. 2. The composition for use according to claim 1, wherein the iNOS inhibitor is selected from the group consisting of GW274150 ((2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid), GW273629 ((2R)-2-amino-3-[2-(1-aminoethylideneamino)ethylsulfonyl]propanoic acid), Aminoguanidine (AG) (2-aminoguanidine), and clotrimazole, or any pharmaceutically acceptable salts thereof. 3. The composition for use according to claim 1 or 2, wherein the iNOS inhibitor is GW274150, or any pharmaceutically acceptable salts thereof. 4. The composition for use according to any of claims 1 to 3, wherein the patient is suffering from a disease selected from the list consisting of bicuspid aortic valve; a syndromic thoracic aortic aneurysm (TAA) such as Marfan Syndrome, vascular Ehlers Danlos, Loeys Dietz Syndrome (Types 1 and 2), and Familial thoracic aortic aneurysm and dissection (familial TAAD), a non-syndromic TAA. 5. The composition for use according to claim 4 wherein the patient is suffering from Marfan syndrome (MFS). 6. The composition for use according to any of the claims 1 to 3, wherein such use is in a medical therapy directed at preventing, limiting and reverting the progressive TAA expansion in syndromic and non-syndromic presentations of the disease. 7. The composition for use according to any of claims 1 to 3, wherein such use is in a medical therapy directed at preventing, limiting or reverting the progression of the thoracic aortic aneurysm (TAA). 8. The composition for use according to claim 7, wherein the progression of the thoracic aortic aneurysm (TAA) is limited or reverted. 9. The composition for use according to any of claims 6 to 8, wherein the syndromic presentation of the disease is Marfan syndrome.